Table 7.
Characteristics, main results, and limitations of the included study focusing on rosacea. Details about the composition of the preparation are given in Table S1 (Supplementary Materials).
| Author(s) (Publication Year; Country) | Study Design (n) | Intervention (n) | Control (n) | Outcome Measure(s) | Study Duration (Evaluation Period) | Main Results | Limitations |
|---|---|---|---|---|---|---|---|
| Ebneyamin et al. (2019; Iran) [59] | Randomized, double-blind, placebo-controlled, prospective clinical trial (35) | 2.5% TTO 1 in permethrin gel (35) | Vehicle gel (35) | —SSSB 2 (mean Dd/cm2
3) —Erythema, papule and pustules, flushing, telangiectasia, edema, plaque, and stinging were monitored via photographs —Monitoring ADRs 4 |
12 weeks (baseline; 2, 5, 8, and 12 weeks) | —After 12 weeks, the mean Dd/cm2 3 on the treatment side were significantly decreased compared to the placebo side —After 12 weeks, a significant improvement in the papules and pustules, burning, stinging, and dry appearance were observed on the treatment side and not on the placebo side —Plaques, telangiectasia, flushing, and edema did not change on both sides —Mild-to-moderate ADRs 4 were reported by most of the individuals on both sides of their face with skin dryness, erosion, burning, and stinging being prevalent |
—Risk of cross-contamination —No demographics reported —Small sample size —No distinction between the effect of permethrin and TTO 1 |
1 TTO: tea tree oil. 2 SSSB: standard skin surface biopsy. 3 Dd/cm2: Demodex density per cm2. 4 ADRs: adverse drug reactions.